Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
China Resources Jiangzhong Pharmaceutical Co EBITDA Margin % Related Terms
China Resources Jiangzhong Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Jiangzhong Pharmaceutical Co EBITDA Margin % Chart
China Resources Jiangzhong Pharmaceutical Co Annual Data
SHSE:600750 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Jiangzhong Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Jiangzhong Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) has a EBITDA Margin % of 34.82% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Resources Jiangzhong Pharmaceutical Co and its competitors. This is 27% above median its historical median of 27.34. Over the past decade, China Resources Jiangzhong Pharmaceutical Co's EBITDA Margin % has ranged from 22.64 to 35.35. According to the industry distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #134 out of 961 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is China Resources Jiangzhong Pharmaceutical Co's EBITDA Margin % too high?
China Resources Jiangzhong Pharmaceutical Co's current EBITDA Margin % of 34.82% is 27% above median its 10-year median of 27.34. Over the past 10 years, this metric has ranged from a low of 22.64 to a high of 35.35. The Drug Manufacturers industry median EBITDA Margin % is 12.49. China Resources Jiangzhong Pharmaceutical Co's value of 34.82% is 178.8% above this industry median. Based on the distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #134 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Resources Jiangzhong Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Jiangzhong Pharmaceutical Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #134 out of 961 companies for EBITDA Margin %. This places China Resources Jiangzhong Pharmaceutical Co in the top 14% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. China Resources Jiangzhong Pharmaceutical Co's value of 34.82% is 178.8% above this benchmark. Historically, China Resources Jiangzhong Pharmaceutical Co's own EBITDA Margin % has ranged from 22.64 to 35.35 over the past decade. While the company's 10-year median is 27.34 vs. the industry median of 12.49, China Resources Jiangzhong Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Jiangzhong Pharmaceutical Co's current EBITDA Margin % of 34.82% is 178.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Resources Jiangzhong Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Jiangzhong Pharmaceutical Co's current EBITDA Margin % is 34.82%, which is 27% above median its own 10-year median of 27.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Jiangzhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥21.28, compared to a current price of ¥24.70 — trading 16.1% above its estimated fair value. The current EBITDA Margin % is 34.82%, which is 27% above median its 10-year median of 27.34 and 178.8% above the Drug Manufacturers industry median of 12.49. China Resources Jiangzhong Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For China Resources Jiangzhong Pharmaceutical Co (SHSE:600750), the current EBITDA Margin % is 34.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥24.70 is trading 16.1% above its estimated GF Value™ of ¥21.28.
GuruFocus considers China Resources Jiangzhong Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600750:
EBITDA Margin %: 34.82% (27% above median its 10-year median of 27.34)
GF Value™: ¥21.28 vs. price of ¥24.70 (16.1% above fair value)
Industry Position: 178.8% above the Drug Manufacturers median (#134 of 961)
No single metric tells the full story. See the SHSE:600750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Jiangzhong Pharmaceutical Co Business Description
China Resources Jiangzhong Pharmaceutical Co Ltd is engaged in the research and development, production, and sale of over-the-counter pharmaceuticals and health-related products, including functional foods. Its business activities also include the production and sale of proprietary Chinese medicines and chemical drugs.
91GF Score
Get the complete analysis for SHSE:600750
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600750 has been successfully added to your 
